PosterSessionOnline

EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER

SLD Summit 2026

26-28 February, Budapest

N. Poster

Poster title

Applicant name

Status


1-PT2	A novel machine learning-based algorithm improves risk stratification of patients with MASLD compared to FIB-4	Kamela Gjini	Received

1-PO4	The benefits of assessing skeletal muscle density rather than muscle mass as an indicator of metabolic disturbances in individuals with overweight: a cross-sectional study	Nicolas Lanthier	Received

1-PO6	Hepatocyte-specific DNMT1 deficiency aggravates hepatic inflammation and fibrosis in MASH	Lina Jegodzinski	Received

1-PO2	MASLD or MetALD? Unveiling the Role of Alcohol in Liver Disease Progression in Diabetic Patients	Ermina Stratina	Received

1-PO1	Cardiometabolic Stratification Reveals Heterogeneous Hepatocellular Carcinoma Risk in MASLD with Advanced Fibrosis	Mario Romeo	Received

2-PO3	PNPLA3 and TM6SF2 genotypes with diabetes identify MASLD patients at high risk of advanced fibrosis	DongYun KIM	Received

2-PO8	Targeting RIPK3 as a mediator of hepatocyte-macrophage crosstalk in MASLD	Mariana Alves	Received

2-PO4	The impact of dietary interventions on liver health biomarkers in individuals with MASLD and MetALD: a systematic literature review and meta-analysis of RCTs	Ute M Stern	Received

2-PO5	Gut dysbiosis and metabolic alterations contribute to hepatic iron overload in a high-fat diet induced rat model of metabolic-dysfunction associated steatotic liver disease	Sahiba Chahal	Received

2-PO2	Novel Trends in Liver Transplantation for MASLD and ALD: Emerging Epidemiology, Allocation & Post-Transplant Challenges	Ekram Hasanin	Received

2-PT1	Steatotic liver disease is associated with frailty and lower muscle density compared to other liver diseases in patients with cirrhosis evaluated for liver transplantation: a cross-sectional study	Salomé Declerck	Received

2-PO1	High risk of potential resmetirom-drug interactions in older adults with metabolic dysfunction-associated steatotic liver disease – a modelling analysis using data from the ASPREE trial	Daniel Clayton-Chubb	Received

2-PT2	Impact of fibrotic MASH as a new indication on semaglutide eligibility in the U.S. adult population	Laurens A. van Kleef	Received

2-PO6	Hepatic antifibrotic response by fibrogenesis markers in patients with MASLD undergoing a 6-month randomized dietary trial.	Angelo Armandi	Received

3-PO3	Evaluating non-invasive screening strategies for identifying treatment-eligible fibrotic MASH in MASLD patients	Laurens A. van Kleef	Received

3-PO5	Metabolome analysis revealed red flag signatures for the identification of MASLD risk across patients with similar dysmetabolic traits	Miriam Longo	Received

3-PO1	Simplified Metabolic dysfunction Associated Fibrosis-5 (sMAF-5) score to identify at-risk liver fibrosis and to predict prognosis	Laurens Van Kleef	Received

3-PO2	Monocyte PLIN2 expression is a metabolic marker of obesity and metabolic dysfunction-associated steatohepatitis (MASH), independent of type 2 diabetes, reflecting an altered metabolomic profile	Patrizia Infelise	Received

3-PO6	Metabolic overload alters secretion and molecular signature of extracellular vesicles released by hepatocytes and stellate cells	Rachel Javorova	Received

3-PO8	The association between adipose tissue dysfunction and MASH severity is mediated by insulin resistance, regardless of BMI	Silvia Sabatini	Received

3-PO4	MARC1 p.A165 ablation reduces hepatocellular carcinoma aggressiveness in vitro and in vivo	Lohitesh Kovooru	Received

3-PT2	Acute response of hepatic fat content to consuming simple sugar alongside fat	Petr Kordac	Received

3-PO7	Modulation of inflammation in the liver–adipose tissue axis by extra virgin olive oil–derived polyphenolic compounds in metabolic dysfunction–associated steatohepatitis	Milos Mihajlovic	Received

3-PT1	Withdrawal of semaglutide results in weight regain, increased alcohol intake and metabolic disorders in a diet-induced obese hamster model of MetALD	Francois Briand	Received

4-PO3	The Potential Role of A gut hormone Expression in MASLD Patients	Abdel Ghani Badran	Received

4-PT2	The chronic exposure to Bisphenol A influences trained immunity and induces immunometabolic innate cells reprogramming, promoting metabolic dysfunction associated steatotic liver disease progression	Mario Romeo	Received

4-PO5	Combined drug and diet treatment lead to lipid remodeling, mitochondrial repair in Metabolic dysfunction-associated steatotic hepatitis	Céline GUILLAUME	Received

4-PO8	Liver stiffness dynamics in patients with metabolic dysfunction-associated steatotic liver disease: a prospective real-life study	Stéphanie André-Dumont	Received

4-PO4	Circulating cell-free DNA and 5-methylcytosine correlated with hepatic damage and death patterns in a progressive model of metabolic dysfunction-associated steatotic liver disease	Giulia Andolina	Received

4-PO2	Repeatability and reproducibility of hepatic steatosis quantification by controlled attenuation parameter across different stages of steatotic liver disease	Yannick Marcour	Received

5-PO6	External validation of the LiverPRO algorithm for liver fibrosis risk assessment in U.S. representative adults	Laurens A. van Kleef	Received

5-PO2	Association of anthropometabolic indicators with telomere length in patients with metabolic dysfunction-associated steatotic liver disease	Vilena Chupina	Received

5-PO8	Clinical relevance of repeating FIB-4 in the screening strategy for identifying MASLD-related advanced fibrosis	Yasmina Chouik	Received

5-PT2	Modulation of interactions between mitochondria and the endoplasmic reticulum by resmetirom in MASLD	Théo ROUSSEAUX	Received

5-PO3	Commonly associated MASLD-related genetic variants do not confer an increased risk of mortality in older adults with MASLD – a post-hoc analysis of the ASPREE trial	Daniel Clayton-Chubb	Received

5-PO4	Clinical spectrum of children seen in Metabolic Dysfunction Associated Liver Disease (MASLD) clinic in a quaternary UK referral centre	Jessica A Eldredge	Received

5-PO7	The influence of coagulation homeostasis disorders on the development of obstetric complications in pregnant women with metabolic-associated steatohepatitis and dyslipidemia	Lina Bahniy	Received

5-PO1	The Potential Role of Resistin, Interleukin-6, and NT-proBNP in the Development of Cardiac Disease among Patients with Type 2 Diabetes Mellitus	Mohamed Abdel-Samiee	Received

6-PO2	Pilot case-control GWAS approach to discover novel genetic variants associated with Metabolic Dysfunction-Associated Steatotic Liver Disease	Francesca DAmbrosio	Received

6-PO8	Minimal detectable change for non-invasive monitoring of steaotic liver disease	Georg Semmler	Received

6-PO5	Longitudinal changes of liver elastography, FIB4 and Agile3+ add prognostic significance to baseline values in patients with Metabolic dysfunction Associated Steatotic Liver Disease (MASLD)	Lucrezia Petrucci	Received

6-PO1	Comparative performance of non-invasive models for detecting clinically significant portal hypertension in masld	Zouhir Gadi	Received

6-PO4	Adipose tissue insulin resistance is a marker and a major driver of severe metabolic dysfunction associated steatohepatitis	Nateneal Beyene	Received

6-PO3	ADAPT and VCTE show comparable performance for identifying patients living with MASH having F2-F3 or F4 histological proven fibrosis: Implications for selecting patients eligible for therapy	Diana Leeming	Received

6-PO7	Metabolic ferroptosis as targetable signature for the genetic subtype of MASLD	Erika Paolini	Received

6-PO6	Picroside I and II prevent fatty acid induced steatosis via modulation of mitochondrial biogenesis and autophagy in Huh 7 cells	Swati Katoch	Received

6-PT2	CD8+ T cells are pro-inflammatory, cytotoxic, and clonally expanded in the early stages of fibrosis due to metabolic dysfunction-associated steatohepatitis (MASH)	Wenhao Li	Received

7-PO2	MetALD Prevalence and Screening Discrepancy: Evidence from a Russian Real-World Cohort	Ekaterina Liusina	Received

7-PO3	Global but not liver-specific deletion of the NO receptor protect mice from metabolic dysfunction-associated steatotic liver disease	Muhammad Ashfaq Khan	Received

7-PO1	Anti-sonic hedgehog immunohistochemistry accurately diagnosis ballooning degeneration in both metabolic dysfunction-associated steatotic liver disease and alcohol-related liver disease	Guillaume Henin	Received

7-PO8	Relationship between thyroid function and the development of liver and cardiovascular events in patients with MASLD	Diego Rojo Lázaro	Received

7-PO5	Refined deuterium tracing of hepatic de novo lipogenesis reveals lipid fraction–specific effects of obesogenic diets	Lucy Davis	Received

7-PT1	The pFIB scores for pediatric MASLD fibrosis associate with the risk of youth-onset type 2 diabetes in children with obesity	Sander Lefere	Received

7-PO7	Combined effect of Atorvastatin and Ambrisentan on the hemodynamic alterations and liver fibrosis in a translational rat model of MASLD with advanced fibrosis	M Serra Cusidó	Received

8-PO8	Biomarkers of cardiometabolic risks for disease severity prediction in metabolic dysfunction-associated steatotic liver disease patients	Jee-Fu Huang	Received

8-PO4	Prospective evaluation of sodium-glucose cotransporter 2 inhibitors on liver steatosis, fibrosis and metabolic biomarkers in patients with type 2 diabetes and steatotic liver disease	Martina Smoli&263;	Received

8-PO7	Associations between glycaemic indices and non-invasive markers of hepatic steatosis and steatohepatitis in Chinese adults with prediabetes	Victoria To	Received

8-PT1	Mediterranean Diet Improves Metabolic Outcomes and Reprograms Immune-Cell Bioenergetics in Adults With MASLD	Giuseppe De Girolamo	Received

8-PO6	Fumaric Acid as a Novel Non-Invasive Biomarker for Identifying Metabolic Dysfunction-Associated Steatohepatitis in Obese Subjects	Seung Kak Shin	Received

8-PO3	Urinary titin N-fragment level as a marker of both extramyocellular lipid content and hepatic disease severity in steatotic liver disease	Guillaume Henin	Received

8-PO5	Early periportal fibrosis and intrahepatic lipid accumulation in a pig model of obesity	Miranda Dosi	Received

8-PO2	Correlation between serum chitinase-3-like protein 1 levels and liver fibrosis severity in patients with metabolic dysfunction–associated steatotic liver disease	Moongmun Anuntasainont	Received

8-PO1	Association of steatotic liver disease with hypertensive disorders of pregnancy: a systematic review and meta analysis of 74.5 million pregnant individuals	Jacqueline Slobin	Received

9-PO7	Assessing the Enhanced Liver Fibrosis® test for identifying MASLD patients eligible for pharmacological treatment	Laura Pagès	Received

9-PT1	Platelet phenotype and function throughout the spectrum of Metabolic dysfunction-Associated Steatotic Liver Disease	Mirko Zoncapè	Received

9-PO4	Increased diagnosis and risk stratification for MASLD in primary care over the last 20 years: Real-world evidence from over 11.7 million individuals in the UK	Huei-Tyng (Philippe) Huang	Received

9-PO3	Metabolomic fingerprints differentiate disease severity in Metabolic dysfunction-associated steatotic liver disease	Karin Hedin	Received

9-PO2	Severity of liver fibrosis and risk of heart failure with preserved ejection fraction in high-metabolic-risk patients with metabolic dysfunction–associated steatotic liver disease	Anara Chinyayeva	Received

9-PO5	Arterial stiffness in patients with metabolic dysfunction-associated steatotic liver disease	Adelaida Solomon	Received

9-PO6	Attenuation versus backscatter for the non-invasive quantification of hepatic steatosis in metabolic dysfunction–associated steatotic liver disease	Silvia Andaloro	Received

10-PO2	Circulating Mir-122, Mir-34a, and Mir-99a as Potential Predictive Biomarkers of Metabolic Dysfunction-Associated Steatotic Liver Disease	Mohamed Abdel-Samiee	Received

10-PO6	Real-world epidemiology and clinical outcomes in MASLD: A 20-year nationwide analysis of over 23 million individuals in Taiwan´s National Health Insurance Research Database	Huei-Tyng (Philippe) Huang	Received

10-PO8	Two-step algorithm using FIB-4 followed by M2BPGi for high-risk SLD	Shunsuke Sato	Received

10-PO4	Genetic and endocrine determinants of MASLD phenotypes: insights from the PNPLA3–TSH interaction	Mariana M. Ramírez-Mejía	Received

10-PO1	Epigenetic alterations in patients with metabolic dysfunction-associated steatotic liverdisease differ by anthropometric status	Laith Jnied	Received

10-PT1	Biomarkers of collagen formation and degradation are associated with major adverse liver outcomes and esophageal varices	Markus Holmberg	Received

10-PO3	Ceus in masld: towards a non-invasive marker of histological activity	Zouhir Gadi	Received

10-PO5	Performance of clinical criteria to identify candidates for pharmacological treatment in patients with MASLD: impact of the metabolic profile	Alba Jiménez-Masip	Received

10-PO7	Chaperone-mediated autophagy modulates the hepatic proteome and disease severity in MASH	Alexander Ledet	Received

11-PO7	A multidisciplinary care pathway enhances MASLD screening and cardiometabolic management in real-world secondary care.	Monica Cucco	Received

11-PO5	Prevalence and risk factors on the appearance and development of ALD, MASLD and MetALD in Catalonia (Spain)	Eduard Mas-Carrió	Received

11-PO8	Homocysteine as a new indicator of cardiovascular risk and fibrosis in paediatric metabolic dysfunction-associated steatotic liver disease.	Antonella Mosca	Received

11-PO3	Long-term intake of Bicarbonate-Sulfate-Calcium-Magnesium mineral water improves MASLD-related outcomes by modulating intestinal permeability, systemic inflammation, and oxidative stress	Mario Romeo	Received

11-PO2	Depression, Anxiety, and Comorbidities as Key Factors Associated with Fatigue in MASLD: Insights from a Nationwide Study	Anna Sheptulina	Received

12-PO4	MPEP attenuates hepatic steatosis via mGluR5/PKC inhibition and AMPK activation in hepatocytes and liver organoids	Michelangelo Trucchi	Received

12-PO1	Comparative evaluation of MAFLD versus MASLD diagnostic criteria for predicting de novo hepatocellular carcinoma risk in HCV-infected individuals following sustained virological response	Mario Romeo	Received

12-PO8	Transcriptional Dysregulation of Hepatocyte-Specific Factors inChronic Liver Disease: A Potential Biomarker Panel	Sandip Todkar	Received

12-PO7	Efficacy of luseogliflozin in elderly patients with type 2 diabetes and metabolic dysfunction associated steatotic liver disease	Tomonori Fujishima	Received

12-PO6	Liver stiffness as a marker of subclinical atherosclerosis in metabolic syndrome	Calin Cipaian	Received

12-PO5	Inclusion of the fatty liver-associated variants in the clinical workup of patients: Results of an eight years´ experience in a tertiary referral center with genotyping facility	Susanne Weber	Received

12-PO3	Microalgae supplementation attenuates malnutrition-induced steatohepatitis by modulating hepatic lipid Metabolism, iron balance, and gut barrier function in Rats	VINESH SHARMA	Received

13-PO1	Steatosis speaks to the heart: early left ventricular global longitudinal strain impairment in metabolic dysfunction-associated steatotic liver disease	Chiara Giglio	Received

13-PO3	Two-tier screening approach for liver fibrosis stratification in outpatients with type 2 diabetes mellitus: A multicenter cross-sectional study	Mirko Zoncapè	Received

13-PO6	Influence of PNPLA3 rs738409 across body mass index categories in metabolic dysfunction–associated steatotic liver disease (MASLD)	Mariana M. Ramírez-Mejía	Received

13-PO2	Di-lineage liver organoids from human donors recapitulate steatotic liver disease	Tanmoy Dutta	Received

13-PO4	The beneficial effect of extra virgin olive oil major phenolic compounds in an in vitro model of metabolic associated steatohepatitis	Melvin Bernardino	Received

13-PO5	Low ceruloplasmin levels define a distinct non-obese metabolic dysfunction-associated steatotic liver disease phenotype	Rémi Gason	Received

13-PO7	Aldafermin as a promising therapy for metabolic dysfunction–associated steatotic liver disease: evidence from a meta-analysis of randomized trials	Ali Othman	Received

14-PO2	Evaluating alanine aminotransferase as a screening marker for steatotic liver disease in HIV-positive and general populations: A cross-sectional study from Egypt	Heba Abdelmalik	Received

14-PO4	Association Between Neck Circumference and Steatotic Liver Disease: A Systematic Review and Meta-analysis	Cecilia Katzenstein	Received

14-PO7	Weight-adjusted waist index as an anthropometric marker of metabolic- dysfunction associated steatotic liver disease: the role of lipoprotein receptor–related protein 5 gene variants	Kardelen Bü&351;ra Ege Gündüz	Received

14-PO1	Non-invasive assessment of liver histology in MASLD using Multiparametric Ultrasound	Nicholas Viceconti	Received

14-PO3	Diagnostic patterns and fibrosis risk in MASLD-related hepatocellular carcinoma	Mihaela Be?leaga	Received

14-PO5	Diagnostic Utility of the MAF-5 Score for Detecting Significant Fibrosis in Egyptian Metabolic-dysfunction associated steatotic liver disease (MASLD) Patients: Comparison with FIB-4 and NFS	Ahmed Kamal	Received

14-PO8	Investigation of metabolic dysfunction associated steatotic liver disease (MASLD) prevalence in a Hungarian autoimmune liver disease (AILD) patient population	Bence Toth	Received

14-PO6	Depression and Anxiety levels are higher in obese women than in men in a cohort of MASLD patients.	Eleonora Dileo	Received

15-PO2	Diagnostic accuracy of blood-based non-invasive tests for advanced fibrosis in patients with MASLD	Raluca Avram	Received

15-PO3	Performance of non-invasive fibrosis scores in MASLD patients after Sleeve Gastrectomy	matteo cecchin	Received

15-PO7	Dysregulation of the urea cycle enzymes determines a more severe MASLD phenotype in a DIAMOND preclinical model	Carola Zurita Palomo	Received

15-PO5	Detarminants of long-term remnant liver donor fibroprogression	Devapriya Manazhy	Received

15-PO4	Liver steatosis predictors in liver cirrhosis with or without ascites.	Corina Pietrareanu	Received

15-PO6	Obesity – Factor of hepatocarcinogenesis in chronic Hepatitis C	MARILENA STOIAN	Received

16-PO1	Barriers and operational challenges in implementing a multidisciplinary and multicentre clinical study involving laboratories, primary care physicians, and hepatologists: Insights from the CARPA study	Alicia Utrilla-Remesal	Received

16-PO2	Brightfield features for discriminating organoids for application in steatotic liver disease: a pilot study by using artificial intelligence	Flavia Grignaffini	Received

SLD Summit 2026

26-28 February, Budapest

Help Line

Homepage

Personal Area

Search and consult posters online
in an exclusive section
for each poster

ACTIVE FROM 26/02/2026 TO 26/02/2026

Poster
Gallery

Upload
Poster

Featured Poster

Vote poster

Poster Discussion
Forum



		Digital Object Identifier. Official code used to identify documents published on internet; similar to ISBN for books. You may use this code to reference your poster in future scientific publications or CVs. It can be found from anywhere in the world. To find the poster page, log onto www.medra.org and enter the DOI, or enter in your internet browser https://dx.doi.org/ followed by the DOI string asigned to your congress.

About us

Terms and Conditions